All ESCMID Global 2025 articles
-
NewsPotential first new antibiotic for gonorrhoea since the 1990s is effective and safe, finds trial
Gepotidacin could be a new treatment to treat gonorrhoea, protecting against the threat of treatment-resistant gonorrhoea and improving patient treatment experiences, suggests the results of a phase 3 randomised control trial.
-
NewsOropouche virus infections underestimated in Latin America and likely to increase due to climate factors
Environmental factors, such changing temperatures and rainfall, are the main drivers associated with the spread of Oropouche virus (OROV) in Latin America, according to a modelling study.
-
NewsStudies shows new class of antibiotic is effective in tackling MRSA
New research has shown a daily dose of epidermicin NI01 – an antibiotic compound developed by University of Plymouth spinout company Amprologix – is as effective at removing Methicillin-resistant Staphylococcus aureus (MRSA) as the current standard of care.
-
NewsParasitic infection and treatment linked to cancer-related gene activity in the cervix
New research has revealed that Schistosoma haematobium, a parasitic infection affecting millions globally, can trigger cancer-related gene activity in the cervical lining, with changes becoming even more pronounced after treatment.
-
NewsMore than 3 million children died from AMR-related infections in 2022, major study shows
A landmark study presented today at ESCMID Global 2025 has revealed that more than 3 million children worldwide lost their lives in 2022 due to antimicrobial resistance (AMR)-related infections.